FRAZER, Pa., Oct. 27 Cephalon, Inc. (Nasdaq: CEPH) announced today that Bob Repella has joined as Senior Vice President, U.S Pharmaceutical Operations. In this role, Mr. Repella will have responsibility for managing all aspects of the company's U.S. pharmaceutical and commercial operations, including Sales, Marketing, and Health Care Systems for the company's U.S. product portfolio.
Advertisement
Prior to joining Cephalon, Mr. Repella was Executive Vice President and General Manager of the Biopharma Business Unit for Wyeth Pharmaceuticals. In this position, he was responsible for the global portfolio of products that included Wyeth's biologic, Enbrel (R). During his 16 years at Wyeth, Mr. Repella served in various roles in both Marketing and Sales including Executive Vice President Pharmaceutical Sales, Marketing and Operations; Senior Vice President, Pharmaceutical Sales; Vice President, Global Business Manager Enbrel; Vice President U. S. Marketing Musculoskeletal Products; Vice President U. S. Healthcare Systems Sales, and Assistant Vice President National Accounts.
Advertisement
"We are pleased that Bob has decided to join the Cephalon team to help us with our strategy to both grow our current US business and to build a commercial platform for future products in areas such as biologics," said Robert Roche, Executive Vice President, Worldwide Pharmaceutical Operations. "Bob brings a wealth of diverse experience in the pharmaceutical industry, which will be vital to Cephalon as we continue to expand into new therapeutic areas and address the evolving challenges of this industry."
Earlier in his career, Mr. Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co., Inc. and Eli Lilly & Co. Mr. Repella received his Bachelors Degree in Pharmacy from Rutgers University and a Masters in Business Administration from Temple University. He is a member of several boards including BIO, where he also serves on their Executive Committee, and Pennsylvania BIO.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.
Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key affiliates are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.
The company's proprietary products in the United States include: NUVIGIL® (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV], and ACTIQ® (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, continuation of growth of the Cephalon Oncology business, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media: Investors: Sheryl Williams Robert (Chip) Merritt 610-738-6493 610-738-6376 [email protected] [email protected]
SOURCE Cephalon, Inc.
